Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $5.98 in the prior trading day, Vir Biotechnology Inc (NASDAQ: VIR) closed at $5.84, down -2.34%. In other words, the price has decreased by -$2.34 from its previous closing price. On the day, 1.01 million shares were traded. VIR stock price reached its highest trading level at $6.12 during the session, while it also had its lowest trading level at $5.76.
Ratios:
Our goal is to gain a better understanding of VIR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.25 and its Current Ratio is at 7.25. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In the most recent recommendation for this company, Evercore ISI on September 03, 2025, initiated with a Outperform rating and assigned the stock a target price of $12.
On August 27, 2025, BofA Securities Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $14.
JP Morgan Downgraded its Overweight to Neutral on January 29, 2024, whereas the target price for the stock was revised from $23 to $9.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 01 ’25 when SVF Endurance (Cayman) Ltd sold 191,854 shares for $5.98 per share. The transaction valued at 1,147,786 led to the insider holds 13,728,924 shares of the business.
SATO VICKI L sold 22,000 shares of VIR for $132,070 on Dec 01 ’25. The Director now owns 1,188,391 shares after completing the transaction at $6.00 per share. On Nov 26 ’25, another insider, SVF Endurance (Cayman) Ltd, who serves as the 10% Owner of the company, sold 127,938 shares for $6.39 each. As a result, the insider received 817,652 and left with 13,982,271 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VIR now has a Market Capitalization of 812490176 and an Enterprise Value of 406152192. For the stock, the TTM Price-to-Sale (P/S) ratio is 48.19 while its Price-to-Book (P/B) ratio in mrq is 1.02. Its current Enterprise Value per Revenue stands at 24.09 whereas that against EBITDA is -0.794.
Stock Price History:
The Beta on a monthly basis for VIR is 1.39, which has changed by -0.17744154 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, VIR has reached a high of $14.45, while it has fallen to a 52-week low of $4.16. The 50-Day Moving Average of the stock is -2.53%, while the 200-Day Moving Average is calculated to be 5.23%.
Shares Statistics:
The stock has traded on average 1.65M shares per day over the past 3-months and 1941670 shares per day over the last 10 days, according to various share statistics. A total of 139.02M shares are outstanding, with a floating share count of 94.03M. Insiders hold about 32.42% of the company’s shares, while institutions hold 54.24% stake in the company. Shares short for VIR as of 1765756800 were 11149646 with a Short Ratio of 6.74, compared to 1763078400 on 10992709. Therefore, it implies a Short% of Shares Outstanding of 11149646 and a Short% of Float of 12.9.
Earnings Estimates
The market rating of Vir Biotechnology Inc (VIR) is currently shaped by the ongoing analysis conducted by 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.6, with high estimates of -$0.45 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$2.98 and -$3.62 for the fiscal current year, implying an average EPS of -$3.3. EPS for the following year is -$2.88, with 9.0 analysts recommending between -$2.16 and -$3.63.
Revenue Estimates
7 analysts predict $19.91M in revenue for. The current quarter. It ranges from a high estimate of $66M to a low estimate of $240k. As of. The current estimate, Vir Biotechnology Inc’s year-ago sales were $12.37MFor the next quarter, 7 analysts are estimating revenue of $2.37M. There is a high estimate of $4.5M for the next quarter, whereas the lowest estimate is $310k.
A total of 9 analysts have provided revenue estimates for VIR’s current fiscal year. The highest revenue estimate was $70.5M, while the lowest revenue estimate was $4.73M, resulting in an average revenue estimate of $20.8M. In the same quarter a year ago, actual revenue was $74.2MBased on 8 analysts’ estimates, the company’s revenue will be $8.63M in the next fiscal year. The high estimate is $15.32M and the low estimate is $1.22M.
